Spots Global Cancer Trial Database for Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
Official Title: Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
Study ID: NCT02698280
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether bevacizumab and nimustine are effective in the treatment of recurrent high grade glioma and to explore whether there is any subgroup being sensitive to this therapeutic protocol.
Detailed Description: Although anti-angiogenesis therapy for glioblastoma(GBM) are showing promise, GBMs often develop resistance to treatment within months or weeks after salvage therapy. There are still no effective markers to predict the response rate to bevacizumab. So the investigators initiate a single-arm Phase II study to evaluate the efficacy and tolerability of bevacizumab and nimustine regimen and to explore the predictive markers in patients with recurrent high-grade glioma.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Huashan hospital, Fudan University, Shanghai, Shanghai, China
Contact Details
Name: Yu Yao, MD, PhD
Affiliation: Department of Neurosurgery, Huashan hospital
Role: STUDY_CHAIR
Name: Daoying Geng, MD
Affiliation: Department of Radiology, Huashan hospital
Role: STUDY_CHAIR
Name: Xiaojie Ding, MD
Affiliation: Department of Neurosurgery, Huashan hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jianbo Wen, MD
Affiliation: Department of Radiology, Huashan hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
